Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study

被引：0
|
作者：
Tomohiro Kaneko
Sakiko Miyazaki
Azusa Kurita
Ryoko Morimoto
Shun Tsuchiya
Naoki Watanabe
Tomoiku Takaku
Norio Komatsu
Tohru Minamino
机构：
[1] Juntendo University Graduate School of Medicine,Department of Cardiovascular Biology and Medicine
[2] Juntendo University Graduate School of Medicine,Department of Hematology
来源：
Cardio-Oncology | / 9卷
关键词：
Tyrosine kinase inhibitors; Chronic myeloid leukemia; Endothelial dysfunction; Uric acid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients
    Jalkanen, Sari E.
    Lahesmaa-Korpinen, Anna-Maria
    Heckman, Caroline A.
    Rantanen, Ville
    Porkka, Kimmo
    Hautaniemi, Sampsa
    Mustjoki, Satu
    EXPERIMENTAL HEMATOLOGY, 2012, 40 (09) : 705 - 714
  • [22] Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
    L. Janssen
    S. J. C. M. Frambach
    N. A. E. Allard
    M. T. E. Hopman
    T. J. J. Schirris
    N. C. Voermans
    R. J. Rodenburg
    N. M. A. Blijlevens
    S. Timmers
    Leukemia, 2019, 33 : 2116 - 2120
  • [23] Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
    Barber, Mary C.
    Mauro, Michael J.
    Moslehi, Javid
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 110 - 114
  • [24] Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
    Dou, Xuelin
    Qin, Yazhen
    Huang, Xiaojun
    Jiang, Qian
    ONCOLOGIST, 2019, 24 (11): : E1141 - E1147
  • [25] Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia
    Jiang, Qian
    Yu, Lu
    Gale, Robert Peter
    BLOOD, 2016, 128 (22)
  • [26] Patients’ and hematologists’ concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia
    Qian Jiang
    Lu Yu
    Robert Peter Gale
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 735 - 741
  • [27] Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
    Janssen, L.
    Frambach, S. J. C. M.
    Allard, N. A. E.
    Hopman, M. T. E.
    Schirris, T. J. J.
    Voermans, N. C.
    Rodenburg, R. J.
    Blijlevens, N. M. A.
    Timmers, S.
    LEUKEMIA, 2019, 33 (08) : 2116 - 2120
  • [28] Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
    Anthony Oyekunle
    Axel R. Zander
    Mascha Binder
    Francis Ayuk
    Tatjana Zabelina
    Maximilian Christopeit
    Thomas Stübig
    Haefaa Alchalby
    Philippe Schafhausen
    Heinrich Lellek
    Christine Wolschke
    Ingo Müller
    Ulrike Bacher
    Nicolaus Kröger
    Annals of Hematology, 2013, 92 : 487 - 496
  • [29] Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia
    Jiang, Qian
    Yu, Lu
    Gale, Robert Peter
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (04) : 735 - 741
  • [30] The Tyrosine Kinase Inhibitor Nilotinib Induces Vascular Adverse Events in Patients With Chronic Myeloid Leukemia and Inhibits Endothelial Function and Angiogenesis
    Kirchmair, Rudolf
    Albrecht-Schgoer, Karin
    Schgoer, Willfried
    Theurl, Markus
    Hadzijusufovic, Emir
    Eisenwort, Gregor
    Herndlhofer, Susanne
    Cerny-Reiterer, Sabine
    Sperr, Wolfgang
    Wolf, Dominik
    Valent, Peter
    CIRCULATION, 2013, 128 (22)
12345